

5 February 2025

Fibrinogen Concentrate, Prothrombin Complex Concentrate, DOAC Antidote, and blood products

I would like to submit an FOI request for the number of vials used and patients treated with the following products at your Trust used in 2024 (total January to December), broken down by brand and size, if possible.

Product	Manufacturer	Size (Units/mg)	Number of vials used (Jan 24 - Dec 24)	Number of patients treated (Jan 24-Dec 24)
Prothrombin Complex Concentrate (PCC)				
Beriplex	CSL Behring	500IU 20ml		
		1000IU 40ml		
Octaplex	Octapharma	500IU 20ml	1869	358
		1000IU 40ml		
Prothromplex	Takeda	600IU 17ml		
FEIBA	Takeda	200IU 10ml		
		500IU 20ml		
		1000IU 40ml		
Others (if any please specify)		(if any please specify)		
Reversal Agents				
Ondexxya (andexanet alfa)	Astrazeneca	4 x 200mg or 5 x 200mg	159	11 (July to December 24 only)
Praxbind (Idaracizumab)	Boehringer Ingelheim	2 x 2.5 g	<5	1 (July to December 24 only)

5 February 2025

Fibrinogen Concentrate (FC)				
RiaSTAP	CSL Behring	1.0g		
FibCLOT	LFB	1.5g		
Fibryga	Octapharma	1.0g	616	209
Others (if any please specify)		(if any please specify)		
Fresh Frozen Plasma (FFP)				
Fresh Frozen Plasma	Blood banks		1317	395
Octaplas	Octapharma		1458	37
Cryoprecipitate				
Cryoprecipitate	Blood banks		456	216
Labile Blood Products				
Whole blood	Blood banks			
Red blood cells	Blood banks		15082	6463
Platelets	Blood banks		4028	1243
Factor XIII				
Fibrogammin	CSL Behring	250IU 4ml		
		1250IU 20ml		

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.